Krystal Biotech Stock Buy Hold or Sell Recommendation
| KRYS Stock | USD 179.19 2.37 1.34% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Krystal Biotech is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Krystal Biotech given historical horizon and risk tolerance towards Krystal Biotech. When Macroaxis issues a 'buy' or 'sell' recommendation for Krystal Biotech, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Krystal Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide. Note, we conduct extensive research on individual companies such as Krystal and provide practical buy, sell, or hold advice based on investors' constraints. Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Krystal |
Execute Krystal Biotech Buy or Sell Advice
The Krystal recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Krystal Biotech. Macroaxis does not own or have any residual interests in Krystal Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Krystal Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Krystal Biotech Trading Alerts and Improvement Suggestions
| Krystal Biotech generated a negative expected return over the last 90 days | |
| Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
| Krystal Biotech has a poor financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: 100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today |
Krystal Biotech Returns Distribution Density
The distribution of Krystal Biotech's historical returns is an attempt to chart the uncertainty of Krystal Biotech's future price movements. The chart of the probability distribution of Krystal Biotech daily returns describes the distribution of returns around its average expected value. We use Krystal Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Krystal Biotech returns is essential to provide solid investment advice for Krystal Biotech.
| Mean Return | -0.15 | Value At Risk | -4.26 | Potential Upside | 3.21 | Standard Deviation | 2.30 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Krystal Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Krystal Stock Institutional Investors
The Krystal Biotech's institutional investors refer to entities that pool money to purchase Krystal Biotech's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Jennison Associates Llc | 2024-06-30 | 520.4 K | Goldman Sachs Group Inc | 2024-06-30 | 422.3 K | Lord, Abbett & Co Llc | 2024-06-30 | 392.2 K | Nuveen Asset Management, Llc | 2024-06-30 | 336.2 K | Credit Suisse First Boston (csfb) | 2024-03-31 | 321.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 318.3 K | Woodline Partners Lp | 2024-06-30 | 291.9 K | Amvescap Plc. | 2024-06-30 | 275.1 K | Ubs Asset Mgmt Americas Inc | 2024-06-30 | 251.8 K | Fmr Inc | 2024-06-30 | 4.3 M | Blackrock Inc | 2024-06-30 | 3.9 M |
Krystal Biotech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 1.4M | 3.7M | (158.4M) | (114.1M) | 82.6M | 86.8M | |
| Change In Cash | 83.8M | 80.8M | 73.0M | (179.3M) | 196.4M | 206.2M | |
| Free Cash Flow | (25.1M) | (40.9M) | (116.3M) | (153.5M) | (100.6M) | (95.6M) | |
| Depreciation | 748K | 1.9M | 2.8M | 4.1M | 5.0M | 5.3M | |
| Other Non Cash Items | 67K | 33K | 1.5M | (690K) | (153.4M) | (145.7M) | |
| Capital Expenditures | 6.4M | 14.8M | 68.3M | 53.0M | 11.8M | 21.6M | |
| Net Income | (19.1M) | (32.2M) | (69.6M) | (140.0M) | 10.9M | 11.5M | |
| End Period Cash Flow | 187.5M | 268.3M | 341.2M | 161.9M | 358.3M | 202.5M | |
| Change To Netincome | 1.3M | 4.0M | 16.8M | 32.5M | 37.4M | 39.3M |
Krystal Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Krystal Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Krystal Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Krystal stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 1.47 | |
σ | Overall volatility | 2.32 | |
Ir | Information ratio | -0.11 |
Krystal Biotech Volatility Alert
Krystal Biotech exhibits very low volatility with skewness of 0.14 and kurtosis of 1.09. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Krystal Biotech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Krystal Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Krystal Biotech Fundamentals Vs Peers
Comparing Krystal Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Krystal Biotech's direct or indirect competition across all of the common fundamentals between Krystal Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Krystal Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Krystal Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Krystal Biotech to competition |
| Fundamentals | Krystal Biotech | Peer Average |
| Return On Equity | 0.14 | -0.31 |
| Return On Asset | 0.0031 | -0.14 |
| Profit Margin | 0.64 % | (1.27) % |
| Operating Margin | 0.30 % | (5.51) % |
| Current Valuation | 4.6 B | 16.62 B |
| Shares Outstanding | 28.73 M | 571.82 M |
| Shares Owned By Insiders | 12.31 % | 10.09 % |
| Shares Owned By Institutions | 87.69 % | 39.21 % |
| Number Of Shares Shorted | 3.52 M | 4.71 M |
| Price To Earning | (6.36) X | 28.72 X |
| Price To Book | 6.14 X | 9.51 X |
| Price To Sales | 30.97 X | 11.42 X |
| Revenue | 50.7 M | 9.43 B |
| EBITDA | (92.22 M) | 3.9 B |
| Net Income | 10.93 M | 570.98 M |
| Cash And Equivalents | 425.56 M | 2.7 B |
| Cash Per Share | 16.58 X | 5.01 X |
| Total Debt | 8.09 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 12.45 X | 2.16 X |
| Book Value Per Share | 29.22 X | 1.93 K |
| Cash Flow From Operations | (88.8 M) | 971.22 M |
| Short Ratio | 13.69 X | 4.00 X |
| Earnings Per Share | 3.94 X | 3.12 X |
| Target Price | 207.22 | |
| Number Of Employees | 229 | 18.84 K |
| Beta | 0.82 | -0.15 |
| Market Capitalization | 5.15 B | 19.03 B |
| Total Asset | 818.36 M | 29.47 B |
| Retained Earnings | (269.83 M) | 9.33 B |
| Working Capital | 554.82 M | 1.48 B |
| Current Asset | 2.05 M | 9.34 B |
| Current Liabilities | 40.74 K | 7.9 B |
Note: Disposition of 5109 shares by Suma Krishnan of Krystal Biotech at 170.3241 subject to Rule 16b-3 [view details]
Krystal Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Krystal . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Krystal Biotech Buy or Sell Advice
When is the right time to buy or sell Krystal Biotech? Buying financial instruments such as Krystal Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Krystal Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Developed Markets Basket ETFs Thematic Idea Now
Developed Markets Basket ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Developed Markets Basket ETFs theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Developed Markets Basket ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.